Joseph J. Ferra Jr. - 16 Dec 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
16 Dec 2023
Net transactions value
-$2,434
Form type
4
Filing time
19 Dec 2023, 16:15:28 UTC
Previous filing
19 Sep 2023
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +12,563 +18% 82,664 16 Dec 2023 Direct F1
transaction ELEV Common Stock Tax liability $2,434 -4,773 -5.8% $0.5100 77,891 16 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -12,563 -14% $0.000000 75,371 16 Dec 2023 Common Stock 12,563 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on June 16, 2022, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.